Population-based study reports trends in opioid agonist treatment for opioid dependence during pregnancy, suggesting a need for strategies to improve treatment retention.
Three in four people in the cohort received OAT during pregnancy, with no statistically significant change in annual prevalence over the 2005-2021 period. Given prior evidence indicating higher rates of treatment discontinuation with buprenorphine versus methadone, the increased buprenorphine use during pregnancy highlights the need for targeted strategies to support treatment retention.
No takes yet. Share an insight, caveat, or question.
Tran et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: